WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 28, 2024.
Third Quarter 2024 Highlights
- Third quarter revenue was $10.60 billion.
- Third quarter GAAP diluted earnings per share (EPS) was $4.25.
- Third quarter adjusted EPS was $5.28.
- Advanced our proven growth strategy, launching a range of high-impact, innovative new products during the quarter. To enable the development of advanced materials, we launched the groundbreaking Thermo Scientific Iliad scanning transmission electron microscope, which integrates a number of our advanced technologies into a user-friendly workflow to enable research of the most sophisticated modern materials down to the atomic level. To advance life sciences research, we launched the Applied Biosystems MagMAX Sequential DNA/RNA kit, which maximizes the isolation of DNA and RNA from blood cancer samples helping researchers identify unique insights into cancer-causing genetic alterations; and the Invitrogen Vivofectamine Delivery Solutions, a novel method for delivering nucleic acids into multiple targets with therapeutic effect, paving the way for groundbreaking new medicines.
- Continued to deepen our trusted partner status with customers to accelerate their innovation and enhance their productivity. In the quarter, we announced a partnership with the National Cancer Institute on the myeloMATCH precision medicine umbrella trial, which will leverage our next-generation sequencing technology to test patients for specific genetic biomarkers to match them more quickly with optimal treatments based on their unique cancer profile. In our pharma services business, we announced the expansion of our Cincinnati, Ohio, and Bend, Oregon, sites to further enhance our solid dose formulation capabilities for our pharma and biotech customers. In our clinical research business, we also announced the expansion of our global laboratory services network with a new bioanalytical lab in Gothenburg, Sweden, which will provide pharma and biotech customers with advanced laboratory services to support all phases of development.
“We are pleased to deliver strong financial results in the third quarter, reflecting another quarter of sequential improvement in growth,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “We continue to deliver differentiated performance through our proven growth strategy and PPI Business System. Our trusted partner status is resonating strongly with customers, and this is translating into meaningful commercial wins.”
Casper added, “Looking ahead, we’re in a great position to deliver on our 2024 objectives, as we continue to create value for all of our stakeholders and build an even brighter future for our company.”
Third Quarter 2024
Revenue for the quarter was $10.60 billion in 2024 versus $10.57 billion in 2023. Growth in revenue, organic revenue and Core organic revenue all improved sequentially from Q2 and were flat versus the prior-year quarter.
GAAP Earnings Results
GAAP diluted EPS in the third quarter of 2024 was $4.25, versus $4.42 in the same quarter last year. GAAP operating income for the third quarter of 2024 was $1.84 billion, compared with $1.86 billion in the year-ago quarter. GAAP operating margin was 17.3%, compared with 17.6% in the third quarter of 2023.
Non-GAAP Earnings Results
Adjusted EPS in the third quarter of 2024 was $5.28, versus $5.69 in the third quarter of 2023. Adjusted operating income for the third quarter of 2024 was $2.36 billion, compared with $2.56 billion in the year-ago quarter. Adjusted operating margin was 22.3%, compared with 24.2% in the third quarter of 2023.
Annual Guidance for 2024
Thermo Fisher is raising its full-year adjusted EPS guidance to a new range of $21.35 to $22.07 versus its previous guidance of $21.29 to $22.07. Revenue guidance continues to be in the range of $42.4 to $43.3 billion.
Use of Non-GAAP Financial Measures
Adjusted EPS, adjusted net income, adjusted operating income, adjusted operating margin, free cash flow, organic revenue growth and Core organic revenue growth are non-GAAP measures that exclude certain items detailed after the tables that accompany this press release, under the heading “Supplemental Information Regarding Non-GAAP Financial Measures.” The reconciliations of GAAP to non-GAAP financial measures are provided in the tables that accompany this press release.
Note on Presentation
Certain amounts and percentages reported within this press release are presented and calculated based on underlying unrounded amounts. As a result, the sum of components may not equal corresponding totals due to rounding.
Conference Call
Thermo Fisher Scientific will hold its earnings conference call today, October 23, at 8:30 a.m. Eastern Daylight Time. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 296868. You may also listen to the call live on the “Investors” section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under the heading “Financials”. A replay of the call will be available under “News, Events & Presentations” through November 6, 2024.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.
Safe Harbor Statement
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers’ capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations; any natural disaster, public health crisis or other catastrophic event; and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our most recent annual report on Form 10-K, and subsequent quarterly reports on Form 10-Q, which are on file with the SEC and available in the “Investors” section of our website under the heading “SEC Filings.” While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
Condensed Consolidated Statements of Income (unaudited) |
|
|
|
|
|
|
|
| ||||||
|
| Three months ended | ||||||||||||
|
| September 28, |
| % of |
| September 30, |
| % of | ||||||
(Dollars in millions except per share amounts) |
| 2024 |
| Revenues |
| 2023 |
| Revenues | ||||||
Revenues |
| $ | 10,598 |
|
|
|
| $ | 10,574 |
|
|
| ||
Costs and operating expenses: |
|
|
|
|
|
|
|
| ||||||
Cost of revenues (a) |
|
| 6,180 |
|
| 58.3 | % |
|
| 6,145 |
|
| 58.1 | % |
Selling, general and administrative expenses (b) |
|
| 1,739 |
|
| 16.4 | % |
|
| 1,578 |
|
| 14.9 | % |
Amortization of acquisition-related intangible assets |
|
| 450 |
|
| 4.2 | % |
|
| 584 |
|
| 5.6 | % |
Research and development expenses |
|
| 346 |
|
| 3.3 | % |
|
| 319 |
|
| 3.0 | % |
Restructuring and other costs (c) |
|
| 45 |
|
| 0.4 | % |
|
| 84 |
|
| 0.8 | % |
Total costs and operating expenses |
|
| 8,759 |
|
| 82.7 | % |
|
| 8,710 |
|
| 82.4 | % |
Operating income |
|
| 1,838 |
|
| 17.3 | % |
|
| 1,864 |
|
| 17.6 | % |
Interest income |
|
| 277 |
|
|
|
|
| 246 |
|
|
| ||
Interest expense |
|
| (356 | ) |
|
|
|
| (359 | ) |
|
| ||
Other income/(expense) (d) |
|
| (16 | ) |
|
|
|
| 14 |
|
|
| ||
Income before income taxes |
|
| 1,742 |
|
|
|
|
| 1,765 |
|
|
| ||
Provision for income taxes (e) |
|
| (99 | ) |
|
|
|
| (53 | ) |
|
| ||
Equity in earnings/(losses) of unconsolidated entities |
|
| (14 | ) |
|
|
|
| (17 | ) |
|
| ||
Net income |
|
| 1,629 |
|
|
|
|
| 1,695 |
|
|
| ||
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest (f) |
|
| — |
|
|
|
|
| (20 | ) |
|
| ||
Net income attributable to Thermo Fisher Scientific Inc. |
| $ | 1,630 |
|
| 15.4 | % |
| $ | 1,715 |
|
| 16.2 | % |
|
|
|
|
|
|
|
|
| ||||||
Earnings per share attributable to Thermo Fisher Scientific Inc.: |
|
|
|
|
|
|
|
| ||||||
Basic |
| $ | 4.26 |
|
|
|
| $ | 4.44 |
|
|
| ||
Diluted |
| $ | 4.25 |
|
|
|
| $ | 4.42 |
|
|
| ||
Weighted average shares: |
|
|
|
|
|
|
|
| ||||||
Basic |
|
| 382 |
|
|
|
|
| 386 |
|
|
| ||
Diluted |
|
| 384 |
|
|
|
|
| 388 |
|
|
| ||
|
|
|
|
|
|
|
|
| ||||||
Reconciliation of adjusted operating income and adjusted operating margin |
|
|
|
|
|
|
|
| ||||||
GAAP operating income |
| $ | 1,838 |
|
| 17.3 | % |
| $ | 1,864 |
|
| 17.6 | % |
Cost of revenues adjustments (a) |
|
| 9 |
|
| 0.1 | % |
|
| 14 |
|
| 0.1 | % |
Selling, general and administrative expenses adjustments (b) |
|
| 21 |
|
| 0.2 | % |
|
| 14 |
|
| 0.1 | % |
Restructuring and other costs (c) |
|
| 45 |
|
| 0.4 | % |
|
| 84 |
|
| 0.8 | % |
Amortization of acquisition-related intangible assets |
|
| 450 |
|
| 4.2 | % |
|
| 584 |
|
| 5.6 | % |
Adjusted operating income (non-GAAP measure) |
| $ | 2,362 |
|
| 22.3 | % |
| $ | 2,560 |
|
| 24.2 | % |
|
|
|
|
|
|
|
|
| ||||||
Reconciliation of adjusted net income |
|
|
|
|
|
|
|
| ||||||
GAAP net income attributable to Thermo Fisher Scientific Inc. |
| $ | 1,630 |
|
|
|
| $ | 1,715 |
|
|
| ||
Cost of revenues adjustments (a) |
|
| 9 |
|
|
|
|
| 14 |
|
|
| ||
Selling, general and administrative expenses adjustments (b) |
|
| 21 |
|
|
|
|
| 14 |
|
|
| ||
Restructuring and other costs (c) |
|
| 45 |
|
|
|
|
| 84 |
|
|
| ||
Amortization of acquisition-related intangible assets |
|
| 450 |
|
|
|
|
| 584 |
|
|
| ||
Other income/expense adjustments (d) |
|
| 3 |
|
|
|
|
| (9 | ) |
|
| ||
Provision for income taxes adjustments (e) |
|
| (139 | ) |
|
|
|
| (192 | ) |
|
| ||
Equity in earnings/losses of unconsolidated entities |
|
| 14 |
|
|
|
|
| 17 |
|
|
| ||
Noncontrolling interests adjustments (f) |
|
| (6 | ) |
|
|
|
| (19 | ) |
|
| ||
Adjusted net income (non-GAAP measure) |
| $ | 2,026 |
|
|
|
| $ | 2,208 |
|
|
| ||
|
|
|
|
|
|
|
|
| ||||||
Reconciliation of adjusted earnings per share |
|
|
|
|
|
|
|
| ||||||
GAAP diluted EPS attributable to Thermo Fisher Scientific Inc. |
| $ | 4.25 |
|
|
|
| $ | 4.42 |
|
|
| ||
Cost of revenues adjustments (a) |
|
| 0.02 |
|
|
|
|
| 0.04 |
|
|
| ||
Selling, general and administrative expenses adjustments (b) |
|
| 0.05 |
|
|
|
|
| 0.03 |
|
|
| ||
Restructuring and other costs (c) |
|
| 0.12 |
|
|
|
|
| 0.22 |
|
|
| ||
Amortization of acquisition-related intangible assets |
|
| 1.17 |
|
|
|
|
| 1.50 |
|
|
| ||
Other income/expense adjustments (d) |
|
| 0.01 |
|
|
|
|
| (0.02 | ) |
|
| ||
Provision for income taxes adjustments (e) |
|
| (0.36 | ) |
|
|
|
| (0.49 | ) |
|
| ||
Equity in earnings/losses of unconsolidated entities |
|
| 0.04 |
|
|
|
|
| 0.04 |
|
|
| ||
Noncontrolling interests adjustments (f) |
|
| (0.02 | ) |
|
|
|
| (0.05 | ) |
|
| ||
Adjusted EPS (non-GAAP measure) |
| $ | 5.28 |
|
|
|
| $ | 5.69 |
|
|
| ||
|
|
|
|
|
|
|
|
| ||||||
Reconciliation of free cash flow |
|
|
|
|
|
|
|
| ||||||
GAAP net cash provided by operating activities |
| $ | 2,167 |
|
|
|
| $ | 2,414 |
|
|
| ||
Purchases of property, plant and equipment |
|
| (271 | ) |
|
|
|
| (332 | ) |
|
| ||
Proceeds from sale of property, plant and equipment |
|
| 20 |
|
|
|
|
| 66 |
|
|
| ||
Free cash flow (non-GAAP measure) |
| $ | 1,915 |
|
|
|
| $ | 2,148 |
|
|
| ||
Business Segment Information |
| Three months ended | ||||||||||||
|
| September 28, |
| % of |
| September 30, |
| % of | ||||||
(Dollars in millions) |
|
| 2024 |
|
| Revenues |
|
| 2023 |
|
| Revenues | ||
|
|
|
|
|
|
|
|
| ||||||
Revenues |
|
|
|
|
|
|
|
| ||||||
Life Sciences Solutions |
| $ | 2,387 |
|
| 22.5 | % |
| $ | 2,433 |
|
| 23.0 | % |
Analytical Instruments |
|
| 1,808 |
|
| 17.1 | % |
|
| 1,754 |
|
| 16.6 | % |
Specialty Diagnostics |
|
| 1,129 |
|
| 10.7 | % |
|
| 1,083 |
|
| 10.2 | % |
Laboratory Products and Biopharma Services |
|
| 5,740 |
|
| 54.2 | % |
|
| 5,728 |
|
| 54.2 | % |
Eliminations |
|
| (467 | ) |
| -4.4 | % |
|
| (424 | ) |
| -4.0 | % |
Consolidated revenues |
| $ | 10,598 |
|
| 100.0 | % |
| $ | 10,574 |
|
| 100.0 | % |
|
|
|
|
|
|
|
|
| ||||||
Segment income and segment income margin |
|
|
|
|
|
|
|
| ||||||
Life Sciences Solutions |
| $ | 845 |
|
| 35.4 | % |
| $ | 872 |
|
| 35.9 | % |
Analytical Instruments |
|
| 451 |
|
| 24.9 | % |
|
| 468 |
|
| 26.7 | % |
Specialty Diagnostics |
|
| 293 |
|
| 25.9 | % |
|
| 283 |
|
| 26.1 | % |
Laboratory Products and Biopharma Services |
|
| 773 |
|
| 13.5 | % |
|
| 937 |
|
| 16.4 | % |
Subtotal reportable segments |
|
| 2,362 |
|
| 22.3 | % |
|
| 2,560 |
|
| 24.2 | % |
Cost of revenues adjustments (a) |
|
| (9 | ) |
| -0.1 | % |
|
| (14 | ) |
| -0.1 | % |
Selling, general and administrative expenses adjustments (b) |
|
| (21 | ) |
| -0.2 | % |
|
| (14 | ) |
| -0.1 | % |
Restructuring and other costs (c) |
|
| (45 | ) |
| -0.4 | % |
|
| (84 | ) |
| -0.8 | % |
Amortization of acquisition-related intangible assets |
|
| (450 | ) |
| -4.2 | % |
|
| (584 | ) |
| -5.6 | % |
Consolidated GAAP operating income |
| $ | 1,838 |
|
| 17.3 | % |
| $ | 1,864 |
|
| 17.6 | % |
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
| ||||||
(a) Adjusted results in 2024 and 2023 exclude charges for the sale of inventory revalued at the date of acquisition and accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations. | ||||||||||||||
(b) Adjusted results in 2024 and 2023 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges associated with product liability litigation. Adjusted results in 2024 also exclude $5 of accelerated depreciation on fixed assets to be abandoned due to facility consolidations. | ||||||||||||||
(c) Adjusted results in 2024 and 2023 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges/credits for pre-acquisition litigation and other matters, net gains on the sale of real estate, and abandoned facility and other expenses of headcount reductions and real estate consolidations. | ||||||||||||||
(d) Adjusted results in 2024 and 2023 exclude net gains/losses on investments. | ||||||||||||||
(e) Adjusted results in 2024 and 2023 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes, and the tax impacts from audit settlements. | ||||||||||||||
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests. | ||||||||||||||
Note: | ||||||||||||||
Consolidated depreciation expense is $291 and $269 in 2024 and 2023, respectively. | ||||||||||||||
Organic and Core organic revenue growth |
| Three months ended |
|
|
| September 28, 2024 |
|
Revenue growth |
| 0% |
|
Acquisitions |
| 1% |
|
Currency translation |
| 0% |
|
Organic revenue growth (non-GAAP measure) |
| 0% |
|
COVID-19 testing revenue |
| 0% |
|
Core organic revenue growth (non-GAAP measure) |
| 0% |
|
|
|
|
|
Note: |
| ||
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. |
| ||
Condensed Consolidated Statements of Income (unaudited) |
|
|
|
|
|
|
|
| ||||||
|
| Nine months ended | ||||||||||||
|
| September 28, |
| % of |
| September 30, |
| % of | ||||||
(Dollars in millions except per share amounts) |
|
| 2024 |
|
| Revenues |
|
| 2023 |
|
| Revenues | ||
Revenues |
| $ | 31,484 |
|
|
|
| $ | 31,971 |
|
|
| ||
Costs and operating expenses: |
|
|
|
|
|
|
|
| ||||||
Cost of revenues (a) |
|
| 18,326 |
|
| 58.2 | % |
|
| 18,905 |
|
| 59.1 | % |
Selling, general and administrative expenses (b) |
|
| 5,156 |
|
| 16.4 | % |
|
| 4,897 |
|
| 15.3 | % |
Amortization of acquisition-related intangible assets |
|
| 1,514 |
|
| 4.8 | % |
|
| 1,775 |
|
| 5.5 | % |
Research and development expenses |
|
| 1,016 |
|
| 3.2 | % |
|
| 1,010 |
|
| 3.2 | % |
Restructuring and other costs (c) |
|
| 151 |
|
| 0.5 | % |
|
| 379 |
|
| 1.2 | % |
Total costs and operating expenses |
|
| 26,163 |
|
| 83.1 | % |
|
| 26,966 |
|
| 84.3 | % |
Operating income |
|
| 5,321 |
|
| 16.9 | % |
|
| 5,005 |
|
| 15.7 | % |
Interest income |
|
| 851 |
|
|
|
|
| 570 |
|
|
| ||
Interest expense |
|
| (1,073 | ) |
|
|
|
| (985 | ) |
|
| ||
Other income/(expense) (d) |
|
| (2 | ) |
|
|
|
| (32 | ) |
|
| ||
Income before income taxes |
|
| 5,096 |
|
|
|
|
| 4,558 |
|
|
| ||
Provision for income taxes (e) |
|
| (507 | ) |
|
|
|
| (151 | ) |
|
| ||
Equity in earnings/(losses) of unconsolidated entities |
|
| (75 | ) |
|
|
|
| (58 | ) |
|
| ||
Net income |
|
| 4,514 |
|
|
|
|
| 4,349 |
|
|
| ||
Less: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest (f) |
|
| 9 |
|
|
|
|
| (16 | ) |
|
| ||
Net income attributable to Thermo Fisher Scientific Inc. |
| $ | 4,505 |
|
| 14.3 | % |
| $ | 4,365 |
|
| 13.7 | % |
|
|
|
|
|
|
|
|
| ||||||
Earnings per share attributable to Thermo Fisher Scientific Inc.: |
|
|
|
|
|
|
|
| ||||||
Basic |
| $ | 11.79 |
|
|
|
| $ | 11.31 |
|
|
| ||
Diluted |
| $ | 11.75 |
|
|
|
| $ | 11.25 |
|
|
| ||
Weighted average shares: |
|
|
|
|
|
|
|
| ||||||
Basic |
|
| 382 |
|
|
|
|
| 386 |
|
|
| ||
Diluted |
|
| 383 |
|
|
|
|
| 388 |
|
|
| ||
|
|
|
|
|
|
|
|
| ||||||
Reconciliation of adjusted operating income and adjusted operating margin |
|
|
|
|
|
|
|
| ||||||
GAAP operating income |
| $ | 5,321 |
|
| 16.9 | % |
| $ | 5,005 |
|
| 15.7 | % |
Cost of revenues adjustments (a) |
|
| 25 |
|
| 0.1 | % |
|
| 73 |
|
| 0.2 | % |
Selling, general and administrative expenses adjustments (b) |
|
| (24 | ) |
| -0.1 | % |
|
| 28 |
|
| 0.1 | % |
Restructuring and other costs (c) |
|
| 151 |
|
| 0.5 | % |
|
| 379 |
|
| 1.2 | % |
Amortization of acquisition-related intangible assets |
|
| 1,514 |
|
| 4.8 | % |
|
| 1,775 |
|
| 5.5 | % |
Adjusted operating income (non-GAAP measure) |
| $ | 6,987 |
|
| 22.2 | % |
| $ | 7,260 |
|
| 22.7 | % |
|
|
|
|
|
|
|
|
| ||||||
Reconciliation of adjusted net income |
|
|
|
|
|
|
|
| ||||||
GAAP net income attributable to Thermo Fisher Scientific Inc. |
| $ | 4,505 |
|
|
|
| $ | 4,365 |
|
|
| ||
Cost of revenues adjustments (a) |
|
| 25 |
|
|
|
|
| 73 |
|
|
| ||
Selling, general and administrative expenses adjustments (b) |
|
| (24 | ) |
|
|
|
| 28 |
|
|
| ||
Restructuring and other costs (c) |
|
| 151 |
|
|
|
|
| 379 |
|
|
| ||
Amortization of acquisition-related intangible assets |
|
| 1,514 |
|
|
|
|
| 1,775 |
|
|
| ||
Other income/expense adjustments (d) |
|
| (8 | ) |
|
|
|
| 36 |
|
|
| ||
Provision for income taxes adjustments (e) |
|
| (190 | ) |
|
|
|
| (534 | ) |
|
| ||
Equity in earnings/losses of unconsolidated entities |
|
| 75 |
|
|
|
|
| 58 |
|
|
| ||
Noncontrolling interests adjustments (f) |
|
| (6 | ) |
|
|
|
| (19 | ) |
|
| ||
Adjusted net income (non-GAAP measure) |
| $ | 6,042 |
|
|
|
| $ | 6,161 |
|
|
| ||
|
|
|
|
|
|
|
|
| ||||||
Reconciliation of adjusted earnings per share |
|
|
|
|
|
|
|
| ||||||
GAAP diluted EPS attributable to Thermo Fisher Scientific Inc. |
| $ | 11.75 |
|
|
|
| $ | 11.25 |
|
|
| ||
Cost of revenues adjustments (a) |
|
| 0.07 |
|
|
|
|
| 0.19 |
|
|
| ||
Selling, general and administrative expenses adjustments (b) |
|
| (0.06 | ) |
|
|
|
| 0.07 |
|
|
| ||
Restructuring and other costs (c) |
|
| 0.39 |
|
|
|
|
| 0.98 |
|
|
| ||
Amortization of acquisition-related intangible assets |
|
| 3.95 |
|
|
|
|
| 4.57 |
|
|
| ||
Other income/expense adjustments (d) |
|
| (0.02 | ) |
|
|
|
| 0.09 |
|
|
| ||
Provision for income taxes adjustments (e) |
|
| (0.50 | ) |
|
|
|
| (1.38 | ) |
|
| ||
Equity in earnings/losses of unconsolidated entities |
|
| 0.20 |
|
|
|
|
| 0.15 |
|
|
| ||
Noncontrolling interests adjustments (f) |
|
| (0.02 | ) |
|
|
|
| (0.05 | ) |
|
| ||
Adjusted EPS (non-GAAP measure) |
| $ | 15.76 |
|
|
|
| $ | 15.87 |
|
|
| ||
|
|
|
|
|
|
|
|
| ||||||
Reconciliation of free cash flow |
|
|
|
|
|
|
|
| ||||||
GAAP net cash provided by operating activities |
| $ | 5,377 |
|
|
|
| $ | 4,683 |
|
|
| ||
Purchases of property, plant and equipment |
|
| (920 | ) |
|
|
|
| (1,074 | ) |
|
| ||
Proceeds from sale of property, plant and equipment |
|
| 40 |
|
|
|
|
| 76 |
|
|
| ||
Free cash flow (non-GAAP measure) |
| $ | 4,498 |
|
|
|
| $ | 3,685 |
|
|
| ||
Business Segment Information |
| Nine months ended | ||||||||||||
|
| September 28, |
| % of |
| September 30, |
| % of | ||||||
(Dollars in millions) |
|
| 2024 |
|
| Revenues |
|
| 2023 |
|
| Revenues | ||
|
|
|
|
|
|
|
|
| ||||||
Revenues |
|
|
|
|
|
|
|
| ||||||
Life Sciences Solutions |
| $ | 7,027 |
|
| 22.3 | % |
| $ | 7,508 |
|
| 23.5 | % |
Analytical Instruments |
|
| 5,277 |
|
| 16.8 | % |
|
| 5,226 |
|
| 16.3 | % |
Specialty Diagnostics |
|
| 3,355 |
|
| 10.7 | % |
|
| 3,300 |
|
| 10.3 | % |
Laboratory Products and Biopharma Services |
|
| 17,221 |
|
| 54.7 | % |
|
| 17,322 |
|
| 54.2 | % |
Eliminations |
|
| (1,397 | ) |
| -4.4 | % |
|
| (1,385 | ) |
| -4.3 | % |
Consolidated revenues |
| $ | 31,484 |
|
| 100.0 | % |
| $ | 31,971 |
|
| 100.0 | % |
|
|
|
|
|
|
|
|
| ||||||
Segment income and segment income margin |
|
|
|
|
|
|
|
| ||||||
Life Sciences Solutions |
| $ | 2,551 |
|
| 36.3 | % |
| $ | 2,525 |
|
| 33.6 | % |
Analytical Instruments |
|
| 1,289 |
|
| 24.4 | % |
|
| 1,321 |
|
| 25.3 | % |
Specialty Diagnostics |
|
| 886 |
|
| 26.4 | % |
|
| 860 |
|
| 26.1 | % |
Laboratory Products and Biopharma Services |
|
| 2,262 |
|
| 13.1 | % |
|
| 2,554 |
|
| 14.7 | % |
Subtotal reportable segments |
|
| 6,987 |
|
| 22.2 | % |
|
| 7,260 |
|
| 22.7 | % |
Cost of revenues adjustments (a) |
|
| (25 | ) |
| -0.1 | % |
|
| (73 | ) |
| -0.2 | % |
Selling, general and administrative expenses adjustments (b) |
|
| 24 |
|
| 0.1 | % |
|
| (28 | ) |
| -0.1 | % |
Restructuring and other costs (c) |
|
| (151 | ) |
| -0.5 | % |
|
| (379 | ) |
| -1.2 | % |
Amortization of acquisition-related intangible assets |
|
| (1,514 | ) |
| -4.8 | % |
|
| (1,775 | ) |
| -5.5 | % |
Consolidated GAAP operating income |
| $ | 5,321 |
|
| 16.9 | % |
| $ | 5,005 |
|
| 15.7 | % |
|
|
|
|
|
|
|
|
| ||||||
|
|
|
|
|
|
|
|
| ||||||
(a) Adjusted results in 2024 and 2023 exclude charges for inventory write-downs associated with large-scale abandonment of product lines, accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations, and charges for the sale of inventory revalued at the date of acquisition. | ||||||||||||||
(b) Adjusted results in 2024 and 2023 exclude certain third-party expenses, principally transaction/integration costs related to recent acquisitions, charges/credits for changes in estimates of contingent acquisition consideration, and charges associated with product liability litigation. Adjusted results in 2024 also exclude $5 of accelerated depreciation on fixed assets to be abandoned due to facility consolidations. | ||||||||||||||
(c) Adjusted results in 2024 and 2023 exclude restructuring and other costs consisting principally of severance, impairments of long-lived assets, net charges for pre-acquisition litigation and other matters, net gains on the sale of real estate, and abandoned facility and other expenses of headcount reductions and real estate consolidations. Adjusted results in 2023 also exclude $26 of contract termination costs associated with facility closures. | ||||||||||||||
(d) Adjusted results in 2024 and 2023 exclude net gains/losses on investments. | ||||||||||||||
(e) Adjusted results in 2024 and 2023 exclude incremental tax impacts for the reconciling items between GAAP and adjusted net income, incremental tax impacts as a result of tax rate/law changes and the tax impacts from audit settlements. | ||||||||||||||
(f) Adjusted results exclude the incremental impacts for the reconciling items between GAAP and adjusted net income attributable to noncontrolling interests. | ||||||||||||||
|
|
|
|
|
|
|
|
| ||||||
Notes: | ||||||||||||||
Consolidated depreciation expense is $852 and $792 in 2024 and 2023, respectively. | ||||||||||||||
For more information related to non-GAAP financial measures, refer to the section titled “Supplemental Information Regarding Non-GAAP Financial Measures” of this release. | ||||||||||||||
| ||||||||||||||
Condensed Consolidated Balance Sheets (unaudited) |
|
|
|
| ||
|
|
|
|
| ||
|
| September 28, |
| December 31, | ||
(In millions) |
| 2024 |
| 2023 | ||
|
|
|
|
| ||
Assets |
|
|
|
| ||
Current assets: |
|
|
|
| ||
Cash and cash equivalents |
| $ | 4,645 |
| $ | 8,077 |
Short-term investments |
|
| 2,000 |
|
| 3 |
Accounts receivable, net |
|
| 8,255 |
|
| 8,221 |
Inventories |
|
| 5,430 |
|
| 5,088 |
Other current assets |
|
| 3,453 |
|
| 3,200 |
Total current assets |
|
| 23,783 |
|
| 24,589 |
Property, plant and equipment, net |
|
| 9,412 |
|
| 9,448 |
Acquisition-related intangible assets, net |
|
| 16,262 |
|
| 16,670 |
Other assets |
|
| 4,180 |
|
| 3,999 |
Goodwill |
|
| 46,726 |
|
| 44,020 |
Total assets |
| $ | 100,364 |
| $ | 98,726 |
|
|
|
|
| ||
Liabilities, redeemable noncontrolling interest and equity |
|
|
|
| ||
Current liabilities: |
|
|
|
| ||
Short-term obligations and current maturities of long-term obligations |
| $ | 4,116 |
| $ | 3,609 |
Other current liabilities |
|
| 10,485 |
|
| 10,403 |
Total current liabilities |
|
| 14,601 |
|
| 14,012 |
Other long-term liabilities |
|
| 5,466 |
|
| 6,564 |
Long-term obligations |
|
| 31,197 |
|
| 31,308 |
Redeemable noncontrolling interest |
|
| 127 |
|
| 118 |
Total equity |
|
| 48,972 |
|
| 46,724 |
Total liabilities, redeemable noncontrolling interest and equity |
| $ | 100,364 |
| $ | 98,726 |
|
|
|
|
| ||
Contacts
Media Contact Information:
Sandy Pound
Thermo Fisher Scientific
Phone: 781-622-1223
E-mail: sandy.pound@thermofisher.com
Investor Contact Information:
Rafael Tejada
Thermo Fisher Scientific
Phone: 781-622-1356
E-mail: rafael.tejada@thermofisher.com
